CSL recently extended its partnership with BaseLaunch, a Swiss organization dedicated to building the next generation of biotech ventures whose discoveries could benefit patients.
Research networks and collaborations provide opportunities for CSL scientists to interact, discover and innovate with external partners. Nine of BaseLaunch’s portfolio companies have gone on to raise $550 million in investment for their ventures.
“BaseLaunch has a strong track record of serving as a growth platform for early-stage ventures developing cutting-edge therapeutics,” said Dr. Adrian Zuercher, CSL’s Vice President, Research Europe.
CSL’s partnership with the accelerator and incubator reflects the company’s commitment to global collaboration by establishing a presence within research hubs and precincts around the world, he said.
“Renewing our partnership will allow us to continue building relationships with highly innovative small companies with the potential to transform their ideas into ground-breaking therapies. Ultimately, our shared goal is to deliver new therapies that may address unmet medical needs for patients,” said Zuercher, who is based in Bern, where CSL has a strong R&D presence and helps form the local biotech ecosystem.
Collaborating with BaseLaunch connects CSL, a global biotech of 32,000 employees, with innovative smaller companies in Switzerland, a global center for biomedical innovation.
“We are truly honored by the support we have received from CSL and the team over the last few years and are excited to continue working together,” said Stephan Emmerth, PhD, BaseLaunch Director of Business Development and Operations. “Their scientific rigor and understanding of early-stage innovation makes them a perfect match for our mission to help build biotech companies that matter – and a premier partner for the European biotech ecosystem at large.”
CSL also has formed partnerships in Bern at the Swiss Institute for Translational and Entrepreneurial Medicine (sitem insel). In 2023, CSL announced an open invitation to scientists to collaborate with the company through a new platform, the Yet2 innovation submission portal.
